[1]
Ahmed, M. et al. 2016. Targeting protein homeostasis in sporadic inclusion body myositis. Science Translational Medicine. 8, 331 (Mar. 2016), 331ra41-331ra41. DOI:https://doi.org/10.1126/scitranslmed.aad4583.
[2]
Amato, A.A. and Greenberg, S.A. 2013. Inflammatory Myopathies. CONTINUUM: Lifelong Learning in Neurology. 19, (Dec. 2013), 1615–1633. DOI:https://doi.org/10.1212/01.CON.0000440662.26427.bd.
[3]
Atherton, P.J. and Smith, K. 2012. Muscle protein synthesis in response to nutrition and exercise. The Journal of Physiology. 590, 5 (Mar. 2012), 1049–1057. DOI:https://doi.org/10.1113/jphysiol.2011.225003.
[4]
Atherton, P.J. and Smith, K. 2012. Muscle protein synthesis in response to nutrition and exercise. The Journal of Physiology. 590, 5 (Mar. 2012), 1049–1057. DOI:https://doi.org/10.1113/jphysiol.2011.225003.
[5]
Baar, K. 2014. Using Molecular Biology to Maximize Concurrent Training. Sports Medicine. 44, S2 (Nov. 2014), 117–125. DOI:https://doi.org/10.1007/s40279-014-0252-0.
[6]
Baar, K. 2014. Using Molecular Biology to Maximize Concurrent Training. Sports Medicine. 44, S2 (Nov. 2014), 117–125. DOI:https://doi.org/10.1007/s40279-014-0252-0.
[7]
Baioni, M.T.C. and Ambiel, C.R. 2010. Spinal muscular atrophy: diagnosis, treatment and future prospects. Jornal de Pediatria. 86, 4 (Aug. 2010), 261–270. DOI:https://doi.org/10.2223/JPED.1988.
[8]
Balance and walking involvement in facioscapulohumeral dystrophy: a pilot study on the effects of custom lower limb orthoses - European Journal of Physical and Rehabilitation Medicine 2013 April;49(2):169-78 - Minerva Medica - Journals: https://www.minervamedica.it/en/journals/europa-medicophysica/article.php?cod=R33Y2013N02A0169.
[9]
Barohn, R.J. et al. 2014. A Pattern Recognition Approach to Patients with a Suspected Myopathy. Neurologic Clinics. 32, 3 (Aug. 2014), 569–593. DOI:https://doi.org/10.1016/j.ncl.2014.04.008.
[10]
Berthelsen, M.P. et al. 2014. Anti-gravity training improves walking capacity and postural balance in patients with muscular dystrophy. Neuromuscular Disorders. 24, 6 (Jun. 2014), 492–498. DOI:https://doi.org/10.1016/j.nmd.2014.03.001.
[11]
Boldrin, L. et al. 2015. Satellite cells from dystrophic muscle retain regenerative capacity. Stem Cell Research. 14, 1 (Jan. 2015), 20–29. DOI:https://doi.org/10.1016/j.scr.2014.10.007.
[12]
Boldrin, L. and Morgan, J.E. 2007. Activating muscle stem cells: therapeutic potential in muscle diseases. Current Opinion in Neurology. 20, 5 (Oct. 2007), 577–582. DOI:https://doi.org/10.1097/WCO.0b013e3282ef5919.
[13]
Briggs, D. and Morgan, J.E. 2013. Recent progress in satellite cell/myoblast engraftment - relevance for therapy. FEBS Journal. 280, 17 (Sep. 2013), 4281–4293. DOI:https://doi.org/10.1111/febs.12273.
[14]
Bushby, K. et al. 2014. Ataluren treatment of patients with nonsense mutation dystrophinopathy. Muscle & Nerve. 50, 4 (Oct. 2014), 477–487. DOI:https://doi.org/10.1002/mus.24332.
[15]
Bushby, K. et al. 2010. Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. The Lancet Neurology. 9, 1 (Jan. 2010), 77–93. DOI:https://doi.org/10.1016/S1474-4422(09)70271-6.
[16]
Bushby, K. et al. 2010. Diagnosis and management of Duchenne muscular dystrophy, part 2: implementation of multidisciplinary care. The Lancet Neurology. 9, 2 (Feb. 2010), 177–189. DOI:https://doi.org/10.1016/S1474-4422(09)70272-8.
[17]
By:Gordon, AM (Gordon, AM); Homsher, E (Homsher, E); Regnier, M (Regnier, M) 2000. Regulation of contraction in striated muscle. PHYSIOLOGICAL REVIEWS PHYSIOLOGICAL REVIEWS. 80, 2 (2000), 853–924.
[18]
By:Jones, SW (Jones, SW); Hill, RJ (Hill, RJ); Krasney, PA (Krasney, PA); O’Conner, B (O’Conner, B); Peirce, N (Peirce, N); Greenhaff, PL (Greenhaff, PL) 2004. Disuse atrophy and exercise rehabilitation in humans profoundly affects the expression of genes associated with the regulation of skeletal muscle mass. FASEB JOURNAL FASEB JOURNAL. 18, 6 (2004). DOI:https://doi.org/10.1096/fj.03-1228fje.
[19]
Carstens, P.-O. and Schmidt, J. 2014. Diagnosis, pathogenesis and treatment of myositis: recent advances. Clinical & Experimental Immunology. 175, 3 (Mar. 2014), 349–358. DOI:https://doi.org/10.1111/cei.12194.
[20]
Cirak, S. et al. 2011. Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study. The Lancet. 378, 9791 (Aug. 2011), 595–605. DOI:https://doi.org/10.1016/S0140-6736(11)60756-3.
[21]
Craig, D.M. et al. 2015. Utilizing small nutrient compounds as enhancers of exercise-induced mitochondrial biogenesis. Frontiers in Physiology. 6, (Oct. 2015). DOI:https://doi.org/10.3389/fphys.2015.00296.
[22]
Cup, E.H. et al. 2007. Exercise Therapy and Other Types of Physical Therapy for Patients With Neuromuscular Diseases: A Systematic Review. Archives of Physical Medicine and Rehabilitation. 88, 11 (Nov. 2007), 1452–1464. DOI:https://doi.org/10.1016/j.apmr.2007.07.024.
[23]
Dalakas, M.C. 2015. Inflammatory Muscle Diseases. New England Journal of Medicine. 372, 18 (Apr. 2015), 1734–1747. DOI:https://doi.org/10.1056/NEJMra1402225.
[24]
Darras, B.T. et al. 2003. Neuromuscular disorders of infancy, childhood, and adolescence: a clinician’s approach. Butterworth-Heinemann.
[25]
Department of Health 2003. Toolkit for Producing Patient Information, Version 2. Crown copyright.
[26]
Dubowitz, V. et al. 2013. Muscle biopsy: a practical approach. Saunders Elsevier.
[27]
Egner, I.M. et al. 2013. A cellular memory mechanism aids overload hypertrophy in muscle long after an episodic exposure to anabolic steroids. The Journal of Physiology. 591, 24 (Dec. 2013), 6221–6230. DOI:https://doi.org/10.1113/jphysiol.2013.264457.
[28]
Feingold, B. et al. 2017. Management of Cardiac Involvement Associated With Neuromuscular Diseases: A Scientific Statement From the American Heart Association. Circulation. 136, 13 (Sep. 2017). DOI:https://doi.org/10.1161/CIR.0000000000000526.
[29]
Fitts, R.H. et al. 2010. Prolonged space flight-induced alterations in the structure and function of human skeletal muscle fibres. The Journal of Physiology. 588, 18 (Sep. 2010), 3567–3592. DOI:https://doi.org/10.1113/jphysiol.2010.188508.
[30]
Forbes, S.C. et al. 2014. Magnetic Resonance Imaging and Spectroscopy Assessment of Lower Extremity Skeletal Muscles in Boys with Duchenne Muscular Dystrophy: A Multicenter Cross Sectional Study. PLoS ONE. 9, 9 (Sep. 2014). DOI:https://doi.org/10.1371/journal.pone.0106435.
[31]
Fuglsang-Frederiksen, A. 2006. The role of different EMG methods in evaluating myopathy. Clinical Neurophysiology. 117, 6 (Jun. 2006), 1173–1189. DOI:https://doi.org/10.1016/j.clinph.2005.12.018.
[32]
Garner, M. et al. 2012. A framework for the evaluation of patient information leaflets. Health Expectations. 15, 3 (Sep. 2012), 283–294. DOI:https://doi.org/10.1111/j.1369-7625.2011.00665.x.
[33]
Glover, G.H. and Schneider, E. 1991. Three-point dixon technique for true water/fat decomposition withB0 inhomogeneity correction. Magnetic Resonance in Medicine. 18, 2 (Apr. 1991), 371–383. DOI:https://doi.org/10.1002/mrm.1910180211.
[34]
Goemans, N.M. et al. 2011. Systemic Administration of PRO051 in Duchenne’s Muscular Dystrophy. New England Journal of Medicine. 364, 16 (Apr. 2011), 1513–1522. DOI:https://doi.org/10.1056/NEJMoa1011367.
[35]
Great Britain. Audit Commission for Local Authorities and the National Health Service in England and Wales. What Seems to Be the Matter Communication (National Health Service Report). Stationery Office.
[36]
Hardie, D.G. and Sakamoto, K. 2006. AMPK: A Key Sensor of Fuel and Energy Status in Skeletal Muscle. Physiology. 21, 1 (Feb. 2006), 48–60. DOI:https://doi.org/10.1152/physiol.00044.2005.
[37]
Harridge, S.D.R. et al. 1996. Whole-muscle and single-fibre contractile properties and myosin heavy chain isoforms in humans. Pflügers Archiv - European Journal of Physiology. 432, 5 (Sep. 1996), 913–920. DOI:https://doi.org/10.1007/s004240050215.
[38]
Hawley, J.A. et al. 2014. Integrative Biology of Exercise. Cell. 159, 4 (Nov. 2014), 738–749. DOI:https://doi.org/10.1016/j.cell.2014.10.029.
[39]
Hoffmann, G.F. et al. eds. 2017. Inherited metabolic diseases: a clinical approach. Springer.
[40]
Hogrel, J.-Y. et al. 2016. Longitudinal functional and NMR assessment of upper limbs in Duchenne muscular dystrophy. Neurology. 86, 11 (Mar. 2016), 1022–1030. DOI:https://doi.org/10.1212/WNL.0000000000002464.
[41]
Hoier, B. and Hellsten, Y. 2014. Exercise-Induced Capillary Growth in Human Skeletal Muscle and the Dynamics of VEGF. Microcirculation. 21, 4 (May 2014), 301–314. DOI:https://doi.org/10.1111/micc.12117.
[42]
Hollak, C.E.M. and Lachmann, R. eds. 2016. Inherited Metabolic Disease in Adults. Oxford University Press.
[43]
Hollak, C.E.M. and Lachmann, R. eds. 2016. Inherited Metabolic Disease in Adults. Oxford University Press.
[44]
Hollingsworth, K.G. et al. 2012. Towards harmonization of protocols for MRI outcome measures in skeletal muscle studies: Consensus recommendations from two TREAT-NMD NMR workshops, 2 May 2010, Stockholm, Sweden, 1–2 October 2009, Paris, France. Neuromuscular Disorders. 22, (Oct. 2012), S54–S67. DOI:https://doi.org/10.1016/j.nmd.2012.06.005.
[45]
Hunter, S. et al. 1998. Techniques to Evaluate Elderly Human Muscle Function: A Physiological Basis. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 53A, 3 (May 1998), B204–B216. DOI:https://doi.org/10.1093/gerona/53A.3.B204.
[46]
Institute of Neurology, Queen Square and National Hospital for Neurology and Neurosurgery (London, England) 2016. Neurology: a Queen Square textbook. John Wiley & Sons, Inc.
[47]
Jeppesen, T.D. et al. 2006. Aerobic training is safe and improves exercise capacity in patients with mitochondrial myopathy. Brain. 129, 12 (Jun. 2006), 3402–3412. DOI:https://doi.org/10.1093/brain/awl149.
[48]
Jones, D.A. et al. 2004. Skeletal muscle from molecules to movement: a textbook of muscle physiology for sport, exercise, physiotherapy and medicine. Churchill Livingstone.
[49]
Kadi, F. 2008. Cellular and molecular mechanisms responsible for the action of testosterone on human skeletal muscle. A basis for illegal performance enhancement. British Journal of Pharmacology. 154, 3 (Jun. 2008), 522–528. DOI:https://doi.org/10.1038/bjp.2008.118.
[50]
Kim, H.K. et al. 2015. Quantitative Skeletal Muscle MRI: Part 2, MR Spectroscopy and T2 Relaxation Time Mapping—Comparison Between Boys With Duchenne Muscular Dystrophy and Healthy Boys. American Journal of Roentgenology. 205, 2 (Aug. 2015), W216–W223. DOI:https://doi.org/10.2214/AJR.14.13755.
[51]
Kinali, M. et al. 2009. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. The Lancet Neurology. 8, 10 (Oct. 2009), 918–928. DOI:https://doi.org/10.1016/S1474-4422(09)70211-X.
[52]
Machado, P. et al. 2013. Update in inclusion body myositis. Current Opinion in Rheumatology. 25, 6 (Nov. 2013), 763–771. DOI:https://doi.org/10.1097/01.bor.0000434671.77891.9a.
[53]
Machado, P.M. et al. 2014. Ongoing Developments in Sporadic Inclusion Body Myositis. Current Rheumatology Reports. 16, 12 (Dec. 2014). DOI:https://doi.org/10.1007/s11926-014-0477-9.
[54]
Machado, P.M. et al. 2014. Sporadic inclusion body myositis. Current Opinion in Neurology. 27, 5 (Oct. 2014), 591–598. DOI:https://doi.org/10.1097/WCO.0000000000000129.
[55]
Marcotte, G.R. et al. 2015. The Molecular Basis for Load-Induced Skeletal Muscle Hypertrophy. Calcified Tissue International. 96, 3 (Mar. 2015), 196–210. DOI:https://doi.org/10.1007/s00223-014-9925-9.
[56]
Matthews, E. and Hanna, M.G. 2014. Skeletal muscle channelopathies. Oxford Textbook of Neuromuscular Disorders. D. Hilton-Jones and M.R. Turner, eds. Oxford University Press. 316–325.
[57]
Mendell, J.R. et al. 2013. Eteplirsen for the treatment of Duchenne muscular dystrophy. Annals of Neurology. 74, 5 (Nov. 2013), 637–647. DOI:https://doi.org/10.1002/ana.23982.
[58]
Mendell, J.R. et al. 2016. Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy. Annals of Neurology. 79, 2 (Feb. 2016), 257–271. DOI:https://doi.org/10.1002/ana.24555.
[59]
Mercuri, E. et al. 2012. Childhood spinal muscular atrophy: controversies and challenges. The Lancet Neurology. 11, 5 (May 2012), 443–452. DOI:https://doi.org/10.1016/S1474-4422(12)70061-3.
[60]
Miguel A Martín 2014. Glycogen Storage Disease Type V. Gene Reviews. (2014).
[61]
Muntoni, F. et al. 2003. Dystrophin and mutations: one gene, several proteins, multiple phenotypes. The Lancet Neurology. 2, 12 (Dec. 2003), 731–740. DOI:https://doi.org/10.1016/S1474-4422(03)00585-4.
[62]
Nancy D Leslie 2018. Very Long-Chain Acyl-Coenzyme A Dehydrogenase Deficiency. Gene Reviews. (2018).
[63]
Nancy Leslie 2017. Pompe Disease. Gene Reviews. (2017).
[64]
Needham, M. and Mastaglia, F.L. 2016. Sporadic inclusion body myositis: A review of recent clinical advances and current approaches to diagnosis and treatment. Clinical Neurophysiology. 127, 3 (Mar. 2016), 1764–1773. DOI:https://doi.org/10.1016/j.clinph.2015.12.011.
[65]
Neuromuscular Disease Center: https://neuromuscular.wustl.edu/.
[66]
O’Brien, T.D. et al. 2010. In vivo measurements of muscle specific tension in adults and children. Experimental Physiology. 95, 1 (Jan. 2010), 202–210. DOI:https://doi.org/10.1113/expphysiol.2009.048967.
[67]
Olivé, M. et al. 2013. Myofibrillar myopathies. Current Opinion in Neurology. 26, 5 (Oct. 2013), 527–535. DOI:https://doi.org/10.1097/WCO.0b013e328364d6b1.
[68]
Olpin, S.E. et al. 2015. The investigation and management of metabolic myopathies. Journal of Clinical Pathology. 68, 6 (Jun. 2015), 410–417. DOI:https://doi.org/10.1136/jclinpath-2014-202808.
[69]
Ørngreen, M.C. and Vissing, J. 2017. Treatment Opportunities in Patients With Metabolic Myopathies. Current Treatment Options in Neurology. 19, 11 (Nov. 2017). DOI:https://doi.org/10.1007/s11940-017-0473-2.
[70]
Paganoni, S. and Amato, A. 2013. Electrodiagnostic Evaluation of Myopathies. Physical Medicine and Rehabilitation Clinics of North America. 24, 1 (Feb. 2013), 193–207. DOI:https://doi.org/10.1016/j.pmr.2012.08.017.
[71]
Puthucheary, Z.A. et al. 2013. Acute Skeletal Muscle Wasting in Critical Illness. JAMA. 310, 15 (Oct. 2013). DOI:https://doi.org/10.1001/jama.2013.278481.
[72]
Rennie, M.J. et al. 2004. Control of the Size of the Human Muscle Mass. Annual Review of Physiology. 66, 1 (Mar. 2004), 799–828. DOI:https://doi.org/10.1146/annurev.physiol.66.052102.134444.
[73]
Rennie, M.J. et al. 2004. Control of the Size of the Human Muscle Mass. Annual Review of Physiology. 66, 1 (Mar. 2004), 799–828. DOI:https://doi.org/10.1146/annurev.physiol.66.052102.134444.
[74]
Ricotti, V. et al. 2013. Long-term benefits and adverse effects of intermittent versus daily glucocorticoids in boys with Duchenne muscular dystrophy. Journal of Neurology, Neurosurgery & Psychiatry. 84, 6 (Jun. 2013), 698–705. DOI:https://doi.org/10.1136/jnnp-2012-303902.
[75]
Ross, J. et al. 2012. Defects in Glycosylation Impair Satellite Stem Cell Function and Niche Composition in the Muscles of the Dystrophic Large Mouse. STEM CELLS. 30, 10 (Oct. 2012), 2330–2341. DOI:https://doi.org/10.1002/stem.1197.
[76]
Rudnik-Schöneborn, S. et al. 2001. The Predictive Value of Achieved Motor Milestones Assessed in 441 Patients with Infantile Spinal Muscular Atrophy Types II and III. European Neurology. 45, 3 (2001), 174–181. DOI:https://doi.org/10.1159/000052118.
[77]
Russman, B.S. et al. 1996. Function changes in spinal muscular atrophy II and III. Neurology. 47, 4 (Oct. 1996), 973–976. DOI:https://doi.org/10.1212/WNL.47.4.973.
[78]
Saudubray, J.M. et al. eds. 2016. Inborn metabolic diseases: diagnosis and treatment. Springer.
[79]
Schröder, R. and Schoser, B. 2009. Myofibrillar Myopathies: A Clinical and Myopathological Guide. Brain Pathology. 19, 3 (Jul. 2009), 483–492. DOI:https://doi.org/10.1111/j.1750-3639.2009.00289.x.
[80]
Shavlakadze, T. and Grounds, M. 2006. Of bears, frogs, meat, mice and men: complexity of factors affecting skeletal muscle mass and fat. BioEssays. 28, 10 (Oct. 2006), 994–1009. DOI:https://doi.org/10.1002/bies.20479.
[81]
Sveen, M.-L. et al. 2013. Resistance training in patients with limb-girdle and becker muscular dystrophies. Muscle & Nerve. 47, 2 (Feb. 2013), 163–169. DOI:https://doi.org/10.1002/mus.23491.
[82]
Thomas Wieser 2017. Carnitine Palmitoyltransferase II Deficiency. Gene Reviews. (2017).
[83]
Velloso, C.P. 2008. Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology. 154, 3 (Jun. 2008), 557–568. DOI:https://doi.org/10.1038/bjp.2008.153.
[84]
Voet, N.B. et al. 2013. Strength training and aerobic exercise training for muscle disease. Cochrane Database of Systematic Reviews. (Jul. 2013). DOI:https://doi.org/10.1002/14651858.CD003907.pub4.
[85]
Wang, C.H. et al. 2007. Consensus Statement for Standard of Care in Spinal Muscular Atrophy. Journal of Child Neurology. 22, 8 (Aug. 2007), 1027–1049. DOI:https://doi.org/10.1177/0883073807305788.
[86]
Wattjes, M.P. and Fischer, D. 2013. Neuromuscular imaging. Springer.
[87]
Wiggs, M.P. 2015. Can endurance exercise preconditioning prevention disuse muscle atrophy? Frontiers in Physiology. 6, (Mar. 2015). DOI:https://doi.org/10.3389/fphys.2015.00063.
[88]
Willcocks, R.J. et al. 2016. Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort. Annals of Neurology. 79, 4 (Apr. 2016), 535–547. DOI:https://doi.org/10.1002/ana.24599.
[89]
Zammit, P.S. et al. 2004. Muscle satellite cells adopt divergent fates. The Journal of Cell Biology. 166, 3 (Aug. 2004), 347–357. DOI:https://doi.org/10.1083/jcb.200312007.
[90]
1983. An information leaflet for surgical patients. Annals of The Royal College of Surgeons of England. 65, 4 (1983).
[91]
1996. Force-velocity properties of human skeletal muscle fibres: myosin heavy chain isoform and temperature dependence. The Journal of Physiology. 495, Pt 2 (1996).
[92]
Neuropathology and Applied Neurobiology. Volume 43, Issue 1.
[93]
1983. Prescription information leaflets: a pilot study in general practice. British Medical Journal (Clinical research ed.). 287, 6400 (1983).
